Human Ontogeny of Drug Transporters: Review and Recommendations of the Pediatric Transporter Working Group

Clinical Pharmacology and Therapeutics

Volumn 98, Issue 3, 2015, Pages 266-287

  Brouwer, K L R ^a   Aleksunes, L M ^b   Brandys, B ^c   Giacoia, G P ^d   Knipp, G ^e   Lukacova, V ^f   Meibohm, B ^g   Nigam, Sk ^h   M Rieder, M ⁱ   Wildt, Sn De ^j  

^a University of North Carolina at Chapel Hill   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d Eunice Kennedy Shriver National Institute   (United States)

^e PURDUE UNIVERSITY   (United States)

^f Simulations Plus Inc   (United States)

^g UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITY OF WESTERN ONTARIO   (Canada)

^j SOPHIA CHILDREN S HOSPITAL   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 3; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 6; ORGANIC ANION TRANSPORTER 2; ORGANIC ANION TRANSPORTER 7; ORGANIC ANION TRANSPORTER B; P-GP PROTEIN; SODIUM BILE ACID COTRANSPORTER; UNCLASSIFIED DRUG; DRUG;

AGE; DRUG DISPOSITION; DRUG INTERACTION; DRUG TRANSPORT; ENVIRONMENTAL EXPOSURE; ETHNIC GROUP; GENETIC DIFFERENCE; HUMAN; INTESTINE; KIDNEY; LIVER; MEDICAL ETHICS; MINOR (PERSON); NONHUMAN; ONTOGENY; PHARMACOGENOMICS; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; VIRUS ENTRY; ANIMAL; CHILD; CHILD DEVELOPMENT; INFANT; MEDICAL RESEARCH; METABOLISM; NEWBORN; PHARMACOKINETICS; PRESCHOOL CHILD; PROCEDURES; TRANSPORT AT THE CELLULAR LEVEL;

AGE FACTORS; ANIMALS; BIOLOGICAL TRANSPORT; BIOMEDICAL RESEARCH; CHILD; CHILD DEVELOPMENT; CHILD, PRESCHOOL; HUMANS; INFANT; INFANT, NEWBORN; MEMBRANE TRANSPORT PROTEINS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 84946399731     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.176     Document Type: Review

References (85)

1. Giacomini, K. M. et al. Membrane transporters in drug development. Nat. Rev. Drug Discov. 9, 215-236 (2010).
2. DeGorter, M. K., Xia, C. Q., Yang, J. J. & Kim, R. B. Drug transporters in drug efficacy and toxicity. Annu. Rev. Pharmacol. Toxicol. 52, 249-273 (2012).
3. Yan, H. et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife 1, e00049 (2012).
4. Ho, R. H. & Kim, R. B. Transporters and drug therapy: implications for drug disposition and disease. Clin. Pharmacol. Ther. 78, 260-277 (2005).
5. Yasuda, S. U., Zhang, L. & Huang, S. M. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin. Pharmacol. Ther. 84, 417-423 (2008).
6. Niemi, M. Transporter pharmacogenetics and statin toxicity. Clin. Pharmacol. Ther. 87, 130-133 (2010).
7. Wilke, R. A. et al. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin. Pharmacol. Ther. 92, 112-117 (2012).
8. Ramsey, L. B. et al. Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood 121, 898-904 (2013).
9. Liu, Y. et al. Association of ABCC2-24C>T polymorphism with highdose methotrexate plasma concentrations and toxicities in childhood acute lymphoblastic leukemia. PLoS One 9, e82681 (2014).
10. Rau, T., Erney, B., Gores, R., Eschenhagen, T., Beck, J. & Langer, T. High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. Clin. Pharmacol. Ther. 80, 468-476 (2006).
11. Fukuda, T. et al. UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipients. Ther. Drug Monit. 34, 671-679 (2012).
12. Venkatasubramanian, R. et al. ABCC3 and OCT1 genotypes influence pharmacokinetics of morphine in children. Pharmacogenomics 15, 1297-1309 (2014).
13. Zamek-Gliszczynski, M. J., Hoffmaster, K. A., Tweedie, D. J., Giacomini, K. M. & Hillgren, K. M. Highlights from the International Transporter Consortium second workshop. Clin. Pharmacol. Ther. 92, 553-556 (2012).
14. Mizuno, T. et al. Developmental trajectory of intestinal MDR1/ABCB1 mRNA expression in children. Br. J. Clin. Pharmacol. 77, 910-912 (2014).
15. Fakhoury, M., Lecordier, J., Medard, Y., Peuchmaur, M. & Jacqz-Agrain, E. Impact of inflammation on the duodenal mRNA expression of CYP3A and P-glycoprotein in children with Crohn's disease. Inflamm. Bowel Dis. 12, 745-749 (2006).
16. Fakhoury, M. et al. mRNA expression of MDR1 and major metabolising enzymes in human fetal tissues. Drug Metab. Pharmacokinet. 24, 529-536 (2009).
17. Miki, Y., Suzuki, T., Tazawa, C., Blumberg, B. & Sasano, H. Steroid and xenobiotic receptor (SXR), cytochrome P450 3A4 and multidrug resistance gene 1 in human adult and fetal tissues. Mol. Cell Endocrinol. 231, 75-85 (2005).
18. van Kalken, C. K. et al. Multidrug resistance gene (P-glycoprotein) expression in the human fetus. Am. J. Pathol. 141, 1063-1072 (1992).
19. Fakhoury, M. et al. Localization and mRNA expression of CYP3A and P-glycoprotein in human duodenum as a function of age. Drug Metab. Dispos. 33, 1603-1607 (2005).
20. Mooij, M. G. et al. Ontogeny of human hepatic and intestinal transporter gene expression during childhood: Age matters. Drug Metab. Dispos. 42, 1268-1274 (2014).
21. Konieczna, A., Erdosova, B., Lichnovska, R., Jandl, M., Cizkova, K. & Ehrmann, J. Differential expression of ABC transporters (MDR1, MRP1, BCRP) in developing human embryos. J. Mol. Histol. 42, 567-574 (2011).
22. Weihrauch, D., Kanchanapoo, J., Ao, M., Prasad, R., Piyachaturawat, P. & Rao, M. C. Weanling, but not adult, rabbit colon absorbs bile acids: flux is linked to expression of putative bile acid transporters. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G439-450 (2006).
23. Hussain, I., Kellett, L., Affleck, J., Shepherd, J. & Boyd, R. Expression and cellular distribution during development of the peptide transporter (PepT1) in the small intestinal epithelium of the rat. Cell Tissue Res. 307, 139-142 (2002).
24. Shen, H., Smith, D. E. & Brosius, F. C. 3rd. Developmental expression of PEPT1 and PEPT2 in rat small intestine, colon, and kidney. Pediatr. Res. 49, 789-795 (2001).
25. Miyamoto, K. et al. Sequence, tissue distribution and developmental changes in rat intestinal oligopeptide transporter. Biochim. Biophys. Acta 1305, 34-38 (1996).
26. Van, L., Pan, Y. X., Bloomquist, J. R., Webb, K. E., Jr. & Wong, E. A. Developmental regulation of a turkey intestinal peptide transporter (PepT1). Poult. Sci. 84, 75-82 (2005).
27. Cizkova, D., Morky, J., Micuda, S., Osterreicher, J. & Martinkova, J. Expression of MRP2 and MDR1 transporters and other hepatic markers in rat and human liver and in WRL 68 cell line. Physiol. Res. 54, 419-428 (2005).
28. Klaassen, C. D. & Aleksunes, L. M. Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol. Rev. 62, 1-96 (2010).
29. Schuetz, E. G., Furuya, K. N. & Schuetz, J. D. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J. Pharmacol. Exp. Ther. 275, 1011-1018 (1995).
30. Tang, L., Hines, R. N., Schuetz, E. G. & Meibohm, B. Age-associated protein expression of P-glycoprotein (MDR1/P-gp) and MRP2 in human pediatric liver. Clin. Pharmacol. Ther. 81, S101 (2007).
31. Ulvestad, M. et al. Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects. Clin. Pharmacol. Ther. 93, 275-282 (2013).
32. Prasad, B. et al. Interindividual variability in hepatic organic aniontransporting polypeptides and P-glycoprotein (ABCB1) protein expression: quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sex. Drug Metab. Dispos. 42, 78-88 (2014).
33. Sharma, S. et al. Hepatobiliary disposition of 17-OHPC and taurocholate in fetal human hepatocytes: A comparison with adult human hepatocytes. Drug Metab. Dispos. 41, 296-304 (2013).
34. Yanni, S. B. et al. Higher clearance of micafungin in neonates compared with adults: role of age-dependent micafungin serum binding. Biopharm. Drug Dispos. 32, 222-232 (2011).
35. Prasad, B., Lai, Y., Lin, Y. & Unadkat, J. D. Interindividual variability in the hepatic expression of the human breast cancer resistance protein (BCRP/ABCG2): effect of age, sex, and genotype. J. Pharm. Sci. 102, 787-793 (2013).
36. Chen, H. L. et al. Developmental expression of canalicular transporter genes in human liver. J. Hepatol. 43, 472-477 (2005).
37. Deo, A. K., Prasad, B., Balogh, L., Lai, Y. & Unadkat, J. D. Interindividual variability in hepatic expression of the multidrug resistance-associated protein 2 (MRP2/ABCC2): quantification by liquid chromatography/tandem mass spectrometry. Drug Metab. Dispos. 40, 852-855 (2012).
38. Hardikar, W., Ananthanarayanan, M. & Suchy, F. J. Differential ontogenic regulation of basolateral and canalicular bile acid transport proteins in rat liver. J. Biol. Chem. 270, 20841-20846 (1995).
39. Thomson, M. M., Hines, R. N., Schuetz, E. G. & Meibohm, B. Ageassociated expression of OATP1B1 and OATP1B3 in human pediatric liver. AAPS J. 14(Suppl 2), W4301 (2012).
40. Hayashi, M., Hui, A., DeKeyser, J., Louie, S., Shou, M. & Xu, L. Evaluation of uptake transporters in human adult and pediatric hepatocytes. Abstracts of the 17th North American Regional ISSX International Society for the Study of Xenobiotics. Drug Metab. Rev. 43, 37-211 (2011).
41. St-Pierre, M. V. et al. Temporal expression profiles of organic anion transport proteins in placenta and fetal liver of the rat. Am. J. Physiol. Regul. Integr. Comp. Physiol. 287, R1505-1516 (2004).
42. Cui, J. Y. et al. Bile acids via FXR initiate the expression of major transporters involved in the enterohepatic circulation of bile acids in newborn mice. Am. J. Physiol. Gastrointest. Liver Physiol. 302, G979-996 (2012).
43. Maher, J. M., Slitt, A. L., Cherrington, N. J., Cheng, X. & Klaassen, C. D. Tissue distribution and hepatic and renal ontogeny of the multidrug resistance-associated protein (Mrp) family in mice. Drug Metab. Dispos. 33, 947-955 (2005).
44. Gao, B., St Pierre, M. V., Stieger, B. & Meier, P. J. Differential expression of bile salt and organic anion transporters in developing rat liver. J Hepatol 41, 201-208 (2004).
45. Lee, H. Y., Wei, D. & Loeken, M. R. Lack of metformin effect on mouse embryo AMPK activity: implications for metformin treatment during pregnancy. Diabetes Metab. Res. Rev. 30, 23-30 (2014).
46. Chen, H. L. et al. Expression of hepatocyte transporters and nuclear receptors in children with early and late-stage biliary atresia. Pediatr. Res. 63, 667-673 (2008).
47. Cui, J. Y. et al. RNA-Seq reveals different mRNA abundance of transporters and their alternative transcript isoforms during liver development. Toxicol. Sci. 127, 592-608 (2012).
48. Pavlova, A., Sakurai, H., Leclercq, B., Beier, D. R., Yu, A. S. & Nigam, S. K. Developmentally regulated expression of organic ion transporters NKT (OAT1), OCT1, NLT (OAT2), and Roct. Am. J. Physiol. Renal Physiol. 278, F635-643 (2000).
49. de Zwart, L. et al. The ontogeny of drug metabolizing enzymes and transporters in the rat. Reprod. Toxicol. 26, 220-230 (2008).
50. Sweet, D. H., Eraly, S. A., Vaughn, D. A., Bush, K. T. & Nigam, S. K. Organic anion and cation transporter expression and function during embryonic kidney development and in organ culture models. Kidney Int. 69, 837-845 (2006).
51. Spaans, E. et al. Expression of kidney drug transporters in children (2014).
52. Sweeney, D. E., Vallon, V., Rieg, T., Wu, W., Gallegos, T. F. & Nigam, S. K. Functional maturation of drug transporters in the developing, neonatal, and postnatal kidney. Mol. Pharmacol. 80, 147-154 (2011).
53. Pacha, J. Development of intestinal transport function in mammals. Physiol. Rev. 80, 1633-1667 (2000).
54. Walker, W. A. Development of the intestinal mucosal barrier. J. Pediatr. Gastroenterol. Nutr. 34(suppl. 1), S33-S39 (2002).
55. Zoetis, T. & Hurtt, M. E. Species comparison of anatomical and functional renal development. Birth Defects Res. B Dev. Reprod. Toxicol. 68, 111-120 (2003).
56. Zampieri, M. et al. Validation of suitable internal control genes for expression studies in aging. Mech. Ageing Dev. 131, 89-95 (2010).
57. Li, R. & Shen, Y. An old method facing a new challenge: re-visiting housekeeping proteins as internal reference control for neuroscience research. Life Sci. 92, 747-751 (2013).
58. Ulvestad, M. et al. Drug metabolizing enzyme and transporter protein profiles of hepatocytes derived from human embryonic and induced pluripotent stem cells. Biochem. Pharmacol. 86, 691-702 (2013).
59. Clancy, B., Darlington, R. B. & Finlay, B. L. Translating developmental time across mammalian species. Neuroscience 105, 7-17 (2001).
60. Nagarajan, R., Darlington, R. B., Finlay, B. L. & Clancy, B. Ttime: An R package for translating the timing of brain development across mammalian species. Neuroinformatics 8, 201-205 (2010).
61. Johnson, T. N. & Rostami-Hodjegan, A. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice. Paediatr. Anaesth. 21, 291-301 (2011).
62. Smits, A., Annaert, P. & Allegaert, K. Drug disposition and clinical practice in neonates: cross talk between developmental physiology and pharmacology. Int. J. Pharm. 452, 8-13 (2013).
63. Bonder, M. J. et al. Genetic and epigenetic regulation of gene expression in fetal and adult human livers. BMC Genomics 15, 860 (2014).
64. Ivanov, M. et al. Ontogeny, distribution and potential roles of 5-hydroxymethylcytosine in human liver function. Genome Biol. 14, R83 (2013).
65. Maher, J. M., Cheng, X., Tanaka, Y., Scheffer, G. L. & Klaassen, C. D. Hormonal regulation of renal multidrug resistance-associated proteins 3 and 4 (Mrp3 and Mrp4) in mice. Biochem. Pharmacol. 71, 1470-1478 (2006).
66. Cheng, X., Maher, J., Lu, H. & Klaassen, C. D. Endocrine regulation of gender-divergent mouse organic anion-transporting polypeptide (Oatp) expression. Mol. Pharmacol. 70, 1291-1297 (2006).
67. Gijsen, V. et al. Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients. J. Heart Lung Transplant. 30, 1352-1359 (2011).
68. Leeder, J. S. & Kearns, G. L. Interpreting pharmacogenetic data in the developing neonate: The challenge of hitting a moving target. Clin. Pharmacol. Ther. 92, 434-436 (2012).
69. Hardwick, R. N., Fisher, C. D., Canet, M. J., Scheffer, G. L. & Cherrington, N. J. Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease. Drug Metab. Dispos. 39, 2395-2402 (2011).
70. Lake, A. D. et al. Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease. Drug Metab. Dispos. 39, 1954-1960 (2011).
71. Salem, F., Johnson, T. N., Barter, Z. E., Leeder, J. S. & Rostami-Hodjegan, A. Age related changes in fractional elimination pathways for drugs: Assessing the impact of variable ontogeny on metabolic drug-drug interactions. J. Clin. Pharmacol. 53, 857-865 (2013).
72. Hosea, N. A. & Jones, H. M. Predicting pharmacokinetic profiles using in silico derived parameters. Mol. Pharm. 10, 1207-1215 (2013).
73. Jones, H. M., Parrott, N., Jorga, K. & Lave, T. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin. Pharmacokinet. 45, 511-542 (2006).
74. Edginton, A. N. & Willmann, S. Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis. Clin. Pharmacokinet. 47, 743-752 (2008).
75. Johnson, T. N., Boussery, K., Rowland-Yeo, K., Tucker, G. T. & Rostami-Hodjegan, A. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin. Pharmacokinet. 49, 189-206 (2010).
76. Johnson, T. N., Rostami-Hodjegan, A. & Tucker, G. T. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin. Pharmacokinet. 45, 931-956 (2006).
77. Parrott, N. et al. Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants. Clin. Pharmacokinet. 50, 613-623 (2011).
78. Minutes for the March 14, 2012 meeting of the Advisory Committee for Pharmaceutical Science and Clinical Pharmacology (PDF-44KB). .
79. Huang, S. M. PBPK as a tool in regulatory review. Biopharm. Drug Dispos. 33, 51-52 (2012).
80. Huang, S. M., Abernethy, D. R., Wang, Y., Zhao, P. & Zineh, I. The utility of modeling and simulation in drug development and regulatory review. J. Pharm. Sci. 102, 2912-2923 (2013).
81. Leong, R. et al. Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials. Clin. Pharmacol. Ther. 91, 926-931 (2012).
82. Krekels, E. H. et al. From pediatric covariate model to semiphysiological function for maturation: part I. Extrapolation of a covariate model from morphine to Zidovudine. CPT Pharmacometrics Syst. Pharmacol. 1, e9 (2012).
83. Nigam, S. K. What do drug transporters really do Nat. Rev. Drug Discov. 14, 29-44 (2015).
84. Kleiber, N., Tromp, K., Mooij, M. G., van de Vathorst, S., Tibboel, D. & de Wildt, S. N. Ethics of drug research in the pediatric intensive care unit. Paediatr. Drugs 17, 43-53 (2015).
85. Vuong, L. T., Blood, A. B., Vogel, J. S., Anderson, M. E. & Goldstein, B. Applications of accelerator MS in pediatric drug evaluation. Bioanalysis 4, 1871-1882 (2012).